AlphAIAlphAI — Financial news for AI agents
simplywall.stSEP 51 min read

Trade Alert: Chief Accounting Officer & MD of Finance in Chicago Of GCM Grosvenor Kathleen Sullivan Has Sold Stock

GCM Grosvenor's Chief Accounting Officer, Kathleen Sullivan, sold $526k worth of shares at $13.16 each, reducing her holding by 47%. This is the largest insider sale in the past year, occurring just below the current share price of $13.27. Insiders own 0.9% of the company, valued at $24m. No insider buying has been recorded in the last year.

Original reporting
simplywall.st
Published Sep 5, 2026, 12:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 5, 2026, 6:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Trade Alert: Chief Accounting Officer & MD of Finance in Chicago Of GCM Grosvenor Kathleen Sullivan Has Sold Stock — source image
Source · simplywall.st
Decision brief

The 30-second read

Low
01

Why it matters

The insider sale is a modest, negative signal but lacks material scale to drive immediate price action.

02

Market read

Limited relevance; primarily of interest to investors tracking insider activity.

03

What to watch

Potential tax‑loss harvesting or personal liquidity needs may explain the transaction.

Relevance 4/10Novelty 4/10Timing: recent filing

Background

GCM Grosvenor Inc. disclosed a Form 4 filing showing its Chief Accounting Officer sold $526 k of stock, reducing her holding by 47%.

Market effects

Sector

None significant; insider sale does not materially affect the broader asset‑management sector.

Regional

No discernible regional impact.

Global

Low; the event is company‑specific and limited in scale.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Executive
    Kathleen Sullivan

    Chief Accounting Officer & MD of Finance, Chicago, sold shares.

Read at source← All news

Related articles

AUG 12
$GCMGMed

GCM Grosvenor Q2 Earnings Call Highlights

GCM Grosvenor (NASDAQ:GCMG) reported Q2 fee-related revenue of $111 million (+11% YoY) and fee-related earnings of $50 million (+21%). Fee-paying AUM was $78 billion. Management expects private markets management fees to rise mid-single digits YoY in Q3. The firm’s ARS results included SpaceX exposure valued at about $3.5B; ARS gross returns were 14% with SpaceX, 10% excluding.

yahoo.com4 min
AUG 10
$GCMGMed

GCM Grosvenor Reports Second Quarter 2026 Earnings Results With GAAP Net Income of $9.6 Million, Fee-Related Earnings Up 21%, and Adjusted Net Income Up 22%…

GCM Grosvenor Inc. (GCMG) filed an SEC Form 8-K — Results of Operations and Financial Condition. PRESS RELEASE GCM Grosvenor Reports Second Quarter 2026 Earnings Results With GAAP Net Income of $9.6 Million, Fee-Related Earnings Up 21%, and Adjusted Net Income Up 22% Year-Over-Year CHICAGO, August 10, 2026 – GCM Grosvenor (Nasdaq: GCMG), a global alternative asset management

SEC EDGAR 8-K6 min
OCT 24
$CMPXMedAI 8/10

Compass Therapeutics publishes tovecimig trial results in JCO

Compass Therapeutics (NASDAQ:CMPX) published Phase 2/3 trial results for tovecimig in the Journal of Clinical Oncology. The study met primary and secondary endpoints, showing improved response rates and progression-free survival in advanced biliary tract cancer patients compared to paclitaxel alone. However, overall survival showed no significant difference, and adverse events were higher in the combination arm. Tovecimig remains investigational.

investing.com2 min